Test bank for Tietz Fundamentals of Clinical Chemistr
and Molecular Diagnostic
8th Edition by Nader Rifai, PhD
Chapters 1 - 4
,Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics 8th Edition Test Bank
DY DY DY DY DY DY DY DY
DY
DY DY
Table of contents:
DY DY
I. Principles Of Laboratory Medicine
DY DY DY DY
Chapter 1. Clinical Chemistry, Molecular Diagnostics, and Laboratory Medicine
DY DY DY DY DY DY DY DY
Chapter 2. Selection and Analytical Evaluation of Methods — With Statistical Techniques
DY DY DY DY DY DY DY DY DY DY DY
Chapter 3. Clinical Evaluation of Methods
DY DY DY DY DY
Chapter 4. Evidence-Based Laboratory Medicine
DY DY DY DY
Chapter 5. Establishment and Use of Reference Values
DY DY DY DY DY DY DY
Chapter 6. Specimen Collection, Processing, and Other Preanalytical Variables
DY DY DY DY DY DY DY DY
Chapter 7. Quality Management
DY DY DY
II. Analytical Techniques And Instrumentation
DY DY DY DY
Chapter 8. Principles of Basic Techniques and Laboratory Safety
DY DY DY DY DY DY DY DY
Chapter 9. Optical Techniques
DY DY DY
Chapter 10. Electrochemistry and Chemical Sensors
DY DY DY DY DY
Chapter 11. Electrophoresis
DY DY
Chapter 12. Chromatography
DY DY
Chapter 13. Mass Spectrometry
DY DY DY
Chapter 14. Enzyme and Rate Analyses
DY DY DY DY DY
Chapter 15. Immunochemical Techniques
DY DY DY
Chapter 16 Automation DY DY
Chapter 17. Point-of-Care Instrumentation
DY DY DY
III. Analytes
D Y
Chapter 18. Amino Acids, Peptides, and Proteins
DY DY DY DY DY DY
Chapter 19. Serum Enzymes
DY DY DY
Chapter 20. Tumor Markers and Cancer Genes
DY DY DY DY DY DY
Chapter 21. Kidney Function Tests — Creatinine, GFR, Urea, and Uric Acid
DY DY DY DY DY DY DY DY DY DY DY
Chapter 22. Carbohydrates
DY DY
Chapter 23. Lipids, Lipoproteins, Apolipoproteins, and Other Cardiac Risk Factors
DY DY DY DY DY DY DY DY DY
Chapter 24. Electrolytes and Blood Gases
DY DY DY DY DY
Chapter 25. Hormones DY DY
Chapter 26. Catecholamines and Serotonin
DY D Y DY DY
Chapter 27. Vitamins, Trace Elements, Nutritional Assessment
DY D Y DY DY DY DY
Chapter 28. Hemoglobin, Iron, and Bilirubin
DY DY DY DY DY
Chapter 29. Porphyrins and Porphyrias
DY DY DY DY
Chapter 30. Therapeutic Drugs and Their Management
DY DY DY DY DY DY
Chapter 31. Clinical Toxicology
DY DY DY
Chapter 32. Toxic Metals
DY D Y DY
IV. Pathophysiology
D Y
Chapter 33. Diabetes DY DY
,Chapter 34. Cardiovascular Disease
DY D Y DY
Chapter 35. Kidney Disease
DY DY DY
Chapter 36. Physiology and Disorders of Water, Electrolyte, and Acid-Base Metabolism
DY D Y DY DY DY DY DY DY DY DY
Chapter 37. Liver Disease
DY DYDY DY
Chapter 38. Gastrointestinal and Pancreatic Diseases
DY D Y DY DY DY
Chapter 39. Disorders of Bone and Mineral Metabolism
DY DYDY DY DY DY DY DY
Chapter 40. Disorders of the Pituitary Gland
DY DYDY DY DY DY DY
Chapter 41. Disorders of the Adrenal Cortex
DY D Y DY DY DY DY
Chapter 42. Thyroid Disorders
DY D Y DY
Chapter 43. Reproduction-Related Disorders
DY D Y DY
Chapter 44. Pregnancy and Prenatal Testing
DY DYDY DY DY DY
Chapter 45. Newborn Screening and Inborn Errors of Metabolism
DY D Y DY DY DY DY DY DY
Chapter 46. Pharmacogenetics
DY DY
V. Molecular Diagnostics
D Y DY
Chapter 47. Principles of Molecular Biology
DY DY DY DY DY
Chapter 48. Nucleic Acid Techniques and Applications
DY DY DY DY DY DY
Chapter 49. Genomes and Nucleic Acid Alterations
DY DY DY DY DY DY
, Chapter 01: Clinical Chemistry, Molecular Diagnostics, and Laboratory Medicine T
DY DY DY DY DY DY DY DY DY
estBank
D
Y
MULTIPLE CHOICE DY
1. An individual working in a clinical chemistry laboratory is married to a sales representati
DY DY DY DY DY DY DY DY DY DY DY DY DY
ve who works for a company that sells chemistry laboratory supplies. When the laborator
DY DY DY DY DY DY DY DY DY DY DY DY DY
y manager requests a list of needed supplies, cost of supplies, and vendors, this individua
DY DY DY DY DY DY DY DY DY DY DY DY DY DY
l onlyrecommends the spouse’s company as the vendor. This is considered to be a(n):
DY D
Y DY DY DY DY DY DY DY DY DY DY DY DY
a. accounting issue. DY
b. possible conflict of interest. DY DY DY
c. maintenance of confidentiality issue. DY DY DY
d. problem with resource allocation. DY DY DY
ANS: B DY
Concern has been raised over the interrelationships between practitioners in the medical fi
DY DY DY DY DY DY DY DY DY DY DY DY
eldand commercial suppliers of drugs, devices, equipment, etc., to the medical profession.
D
Y DY DY DY DY DY DY DY DY DY DY DY
Similarly, relationships have been scrutinized between clinical laboratorians and manufactu
DY DY DY DY DY DY DY DY DY
rers and providers of diagnostic equipment and supplies. These concerns led the National I
DY DY DY DY DY DY DY DY DY DY DY DY DY
nstitutes of Health (NIH) in 1995 to require official institutional review of financial disclo
DY DY DY DY DY DY DY DY DY DY DY DY DY
sure by researchers and management of situations in which disclosure indicates potentialco
DY DY DY DY DY DY DY DY DY DY DY D
Y
nflicts of interest. DY DY
DIF: 1 REF: DYDYDY Page 4-5 DY OBJ: 6 | 7 DY DY DY
2. A patient visits her physician stating that her prescribed painkiller is not working to red
DY DY DY DY DY DY DY DY DY DY DY DY DY DY
uce the pain following her recent surgery. A friend of the patient claims that the same p
DY DY DY DY DY DY DY DY DY DY DY DY DY DY DY DY
ainkiller“worked wonders” to reduce her pain after the same surgery. The physician stat
D
Y DY DY DY DY DY DY DY DY DY DY DY DY
es that the difference in the effect of the drug might be caused by
DY DY DY DY DY DY DY DY DY DY DY DY DY
, which is studied in pharmacogenetics.
DY DY DY DY DY
a. epidemiology
b. an inherited disease DY DY
c. a conflict of interest
DY DY DY
d. a genetic variation in drug-metabolizing enzymes
DY DY DY DY DY
ANS: D DY
Pharmacogenetics is the study of the genetic variation of drug metabolism betw DY DY DY DY DY DY DY DY DY DY DY
eenindividuals.
D
Y
DIF: 1 REF: DYDYD Y Page 3 DY OBJ: 1 DY
3. John works in a molecular diagnostics laboratory and receives a blood sample that has
DY DY DY DY DY DY DY DY DY DY DY DY DY DY
the name of a close friend printed on the bar-
DY DY DY DY DY DY DY DY DY
coded label. The genetic test that is ordered on thefriend’s sample would provide diagn
DY DY DY DY DY DY DY DY DY D
Y DY DY DY DY
ostic information about a disorder that has a poor prognosis, and the test is usually perf
DY DY DY DY DY DY DY DY DY DY DY DY DY DY DY
ormed by John. He asks a fellow employee to analyzethe sample for him and not divul
DY DY DY DY DY DY DY DY DY D
Y DY DY DY DY DY DY
ge the results. This ethical issue concerns:
DY DY DY DY DY DY
a. confidentiality of patient genetic and medical information. DY DY DY DY DY DY
b. a conflict of interest.
DY DY DY
c. resource allocation. DY
d. diagnostic accuracy. DY
